Drug updated on 11/10/2023

Dosage FormInjection (subcutaneous; 140 mg/mL, 420 mg/3.5 mL)
Drug ClassPCSK9 (proprotein convertase subtilisin kexin type 9) inhibitors
Ongoing and
Completed Studies


  • To reduce the risk of myocardial infarction, stroke, and coronary revascularization in adults with established cardiovascular disease (CVD).
  • As an adjunct to diet, alone or in combination with other low-density lipoprotein cholesterol (LDL-C)-lowering therapies, in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), to reduce LDL-C .
  • As an adjunct to diet and other LDL-C-lowering therapies in pediatric patients aged 10 years and older with HeFH, to reduce LDL-C.
  • As an adjunct to other LDL-C-lowering therapies in adults and pediatric patients aged 10 years and older with homozygous familial hypercholesterolemia (HoFH), to reduce LDL-C.

Product Monograph / Prescribing Information

Document TitleYearSource
Repatha (evolocumab) Prescribing Information.2021Amgen Inc., Thousand Oaks, CA

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Efficacy and Safety of Alirocumab and Evolocumab as Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors in Familial Hypercholesterolemia: A Systematic Review and Meta-Analysis2024Current medicinal chemistry
The association between pcsk9 inhibitor use and sepsis: a systematic review and meta-analysis of 20 double-blind, randomized, placebo-controlled trials.2023The American Journal of Medicine
The efficacy of PCSK9 inhibitors on major cardiovascular events and lipid profile in patients with diabetes: a systematic review and meta-analysis of randomized controlled trials.2023European Heart Journal Cardiovascular Pharmacotherapy
Safety and effectiveness of evolocumab during acute and sub-acute phases of acute coronary syndrome (acs): a systematic review and meta-analysis.2023Cureus
Reduction of Cardiovascular Risk Using Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients With Acute Coronary Syndrome: A Systematic Review 2023Cureus
Efficacy and safety of proprotein convertase subtilisin/kexin type 9 inhibitors as adjuvant treatments for patients with hypercholesterolemia treated with statin: a systematic review and network meta-analysis. 2022Frontiers in Pharmacology
PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a Bayesian network meta-analysis. 2022Cardiovascular Diabetology
Additive effects of ezetimibe, evolocumab, and alirocumab on plaque burden and lipid content as assessed by intravascular ultrasound: A PRISMA-compliant meta-analysis.2022Medicine
Comparative efficacy of non-statin lipid-lowering therapies in patients with hypercholesterolemia at increased cardiovascular risk: a network meta-analysis2022Current medical research and opinion
Network Meta-Analysis of Randomized Trials Evaluating the Comparative Efficacy of Lipid-Lowering Therapies Added to Maximally Tolerated Statins for the Reduction of Low-Density Lipoprotein Cholesterol2022Journal of the American Heart Association
The promising novel therapies for familial hypercholesterolemia2022Journal of clinical laboratory analysis
Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on the number needed to treat2022Frontiers in cardiovascular medicine
Exploring the Efficacy of Alirocumab and Evolocumab in Reducing Low-Density Lipoprotein (LDL) Cholesterol Levels in Patients With Familial Hypercholesterolemia: A Systematic Review2022Cureus
Effect of PCSK9 Inhibitor on Blood Lipid Levels in Patients with High and Very-High CVD Risk: A Systematic Review and Meta-Analysis2022Cardiology research and practice
Incremental net benefit of lipid-lowering therapy with PCSK9 inhibitors: a systematic review and meta-analysis of cost-utility studies2022European journal of clinical pharmacology
Meta-analysis of clinical outcomes of PCSK9 modulators in patients with established ASCVD. 2021Pharmacotherapy
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and the risk for neurocognitive adverse events: a systematic review, meta-analysis and meta-regression.2021International Journal of Cardiology
A meta-analysis of medications directed against PCSK9 in familial hypercholesterolemia.2021Atherosclerosis
A Systematic Review and Meta-Analysis of Therapeutic Efficacy and Safety of Alirocumab and Evolocumab on Familial Hypercholesterolemia2021BioMed research international
antibodies in patients with familial hypercholesterolaemia: an updated meta-analysis.2020Endokrynologia Polska
Efficacy and safety of PCSK9 monoclonal antibodies in patients at high cardiovascular risk: an updated systematic review and meta-analysis of 32 randomized controlled trials.2020Advances in Therapy
PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease (review).2020Cochrane Database for Systematic Reviews
Indirect comparison of the efficacy and safety of alirocumab and evolocumab: a systematic review and network meta-analysis.2020European Heart Journal Cardiovascular Pharmacotherapy
Australian public assessment report for evolocumab.2019Australian Government: Department of Health
Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials.2019European Heart Journal
Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines2019Circulation
Effects of PCSK9 inhibitors on LDL cholesterol, cardiovascular morbidity and all-cause mortality: a systematic review and meta-analysis of randomized controlled trials2019Journal of endocrinological investigation

Clinical Practice Guidelines